Shire Receives “Approvable” Letter For Intuniv To Treat ADHD
Shire expects to make a “timely” response to FDA’s concerns, which center on labeling, risk management issues, firm tells “The Pink Sheet” DAILY.
Shire expects to make a “timely” response to FDA’s concerns, which center on labeling, risk management issues, firm tells “The Pink Sheet” DAILY.